Ono Pharma’s endocannabinoid drug ONO-1110 fails five Phase 2 trials, prompting broader concerns

Ono Pharma reported that its experimental endocannabinoid modulator ONO-1110 did not achieve the primary efficacy endpoint in five separate Phase 2 clinical trials.

The failures span multiple indications, suggesting the compound may not deliver the anticipated therapeutic benefit.

In related industry news, Lenz Therapeutics and Molecular Partners disclosed plans to reduce their workforce, citing restructuring efforts.

The brief also mentioned other companies such as GSK, Ascletis, BioMarin, Rigerna and Hisun, though no specific developments were detailed.